EEST Darolutamide receives EU approval in third indication for patients with advanced prostate cancer European Commission ...

Androgen deprivation therapy is a lifesaving therapy used by thousands of men each year, but some patients are warning of ...

The European Commission has granted marketing authorization in the European Union (EU) for German pharma major Bayer’s Nubeqa ...

The constant threat of recurrence feels like the proverbial sword of Damocles — always present, always waiting. If my cancer does return, the now-inert metal seeds scattered through my prostate and ...

EEST Darolutamide receives EU approval in third indication for patients with advanced prostate cancer European Commission granted approval ...

During a live event, Jahan Aghalar, MD, discussed the efficacy and safety of darolutamide plus ADT in mHSPC in the ARANOTE ...

Hormone therapy for metastatic prostate cancer comes in three main types: ADT, androgen synthesis inhibitors, and androgen receptor blockers.

Berlin: Bayer has received marketing authorization from the European Commission in the European Union (EU) for Nubeqa ...

European Union approves Bayer’s Nubeq for patients with advanced prostate cancer: Berlin Tuesday, July 22, 2025, 11:00 Hrs [IST] The European Commission has granted marketing au ...

Pedro C. Barata, MD, MSc, discusses the advantages and disadvantages of darolutamide in metastatic hormone-sensitive prostate ...